RapidEye
Regeneron Pharmaceuticals (NASDAQ: REGN), maker of eye disease therapy Eylea, has acquired Oxular, a UK-based biotech drug developer focused on ophthalmology.
While neither company officially disclosed the deal, former Oxular CEO Mark Gaffney, who currently heads immunology drug developer Calluna Pharma, shared a
